|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0013216,
umls-concept:C0027651,
umls-concept:C0257685,
umls-concept:C0332120,
umls-concept:C0439851,
umls-concept:C0441655,
umls-concept:C0600558,
umls-concept:C0871261,
umls-concept:C1280500,
umls-concept:C1552596,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1947931,
umls-concept:C2911692
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2010-3-31
|
|
pubmed:abstractText |
Pre-clinical studies have demonstrated synergistic anti-tumour effects of chemotherapy (CT) and zoledronic acid (ZOL). Within the AZURE trial, designed to determine whether the addition of ZOL to neoadjuvant therapy improves disease outcomes, a subgroup received neoadjuvant CT. We report a retrospective evaluation comparing pathological response in the primary tumour between treatment groups.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20234364-10080586,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20234364-11709566,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20234364-11870173,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20234364-12435290,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20234364-15197191,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20234364-16077072,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20234364-16507416,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20234364-16606972,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20234364-16757970,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20234364-17683651,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20234364-17701939,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20234364-17785706,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20234364-17941030,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20234364-17998286,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20234364-18258991,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20234364-18380893,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20234364-18423992,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20234364-18695136,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20234364-18701468,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20234364-19213681,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20234364-19621384,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20234364-8912545,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20234364-9215816,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20234364-9704717
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1532-1827
|
|
pubmed:author |
pubmed-author:AZURE (BIG01/04) Investigators,
pubmed-author:BellRR,
pubmed-author:BurkinshawRR,
pubmed-author:CameronDD,
pubmed-author:ColemanR ERE,
pubmed-author:DodwellDD,
pubmed-author:GilMM,
pubmed-author:KeaneM MMM,
pubmed-author:MarshallS JSJ,
pubmed-author:Passos-CoelhoJ LJL,
pubmed-author:RitchieDD,
pubmed-author:ThorpeHH,
pubmed-author:WheatleyDD,
pubmed-author:WinterM CMC
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
30
|
|
pubmed:volume |
102
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1099-105
|
|
pubmed:dateRevised |
2011-7-27
|
|
pubmed:meshHeading |
pubmed-meshheading:20234364-Adult,
pubmed-meshheading:20234364-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20234364-Breast Neoplasms,
pubmed-meshheading:20234364-Diphosphonates,
pubmed-meshheading:20234364-Female,
pubmed-meshheading:20234364-Humans,
pubmed-meshheading:20234364-Imidazoles,
pubmed-meshheading:20234364-Middle Aged,
pubmed-meshheading:20234364-Multivariate Analysis,
pubmed-meshheading:20234364-Neoadjuvant Therapy,
pubmed-meshheading:20234364-Neoplasm, Residual
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer.
|
|
pubmed:affiliation |
Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Sheffield, UK. r.e.coleman@sheffield.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
